Join Bianca Collings on PathPulse: Pathology Innovators in Action as she speaks with Amanda Lowe, a digital pathology pioneer. With over two decades in the field, Amanda's extensive experience includes roles at Bacus Laboratories (first U.S. distributor of the Hamamatsu NanoZoomer) and currently as Managing Director for Visiopharm Corporation (Americas) and SVP of global customer success.

This episode offers inspiring and practical insights into overcoming challenges and maximizing digital pathology's potential.

Transcript: https://lumeadigital.com/digital-pathology-barriers/

Amanda details digital pathology's evolution, highlighting how COVID-19 significantly accelerated adoption, leading to regulatory leniency and proving remote sign-out's value. A key Memorial Sloan Kettering study confirmed 100% diagnostic equivalency between digital and glass.

The conversation then focuses on current barriers:

• Data Security: The increasing risk of breaches with digital patient data, especially with evolving AI capabilities.
• Standards & Interoperability: The challenge of diverse image formats and system requirements, stressing the need for DICOM standardization and expert guidance.
• Regulatory & Reimbursement: Hurdles include the lack of national payment rates for digital pathology CPT codes and the evolving FDA regulation of LDTs.

Amanda champions a collaborative, agile approach to these challenges. She emphasizes that digital pathology is "the right thing to do" and urges the community to "never give up," advocating for continuous learning and collective action to drive the field forward.

Submit questions for our future recordings here: https://lumeadigital.com/ask-a-pathologist-podcast/

Sponsored by the Digital Diagnostic Summit and Lumea.